GSTM1 and GSTT1 Polymorphism in Egyptian Sickle Cell Anemia Patients

M. Aly RABAB1, M. Hasaneen BOTHINA2

1 Mansoura University Faculty of Medicine, Department of Clinical Pathology
2 Mansoura University Faculty of Medicine, Department of Pediatry, Mansoura, EGYPT

ABSTRACT

Glutathione S-transferase gene deletions are known detoxification agents and cause oxidative damage. In different studies, variations in null allele frequency have been observed. We have investigated the prevalence of the GSTM1 and GSTT1 null genotypes in sickle cell disease (SCD) patients. Thirty-seven sickle cell anemia and forty controls were evaluated to determine the frequency of Glutathione S-transferase (GSTM) gene deletions. Complete blood counts were performed by an automated cell analyzer. Hemoglobin F, hemoglobin A, hemoglobin A2 and hemoglobin S were measured and diagnosis of patients was achieved by high performance liquid chromatography. The GST null genotype was determined using polymerase chain reaction (PCR) method. The prevalence of GSTM1-null genotype in SCD was 37.8%, compared to 55.0% in the control group (OR= 0.9, 95% CI= 0.3-2.8, p= 0.24). The frequency of individuals carrying GSTT1 null genotype was higher among SCA patients (64.9%) compared to controls (42.5%) (Odds Ratio, OR= 2.5, 95% Confidence Interval, CI= 1.8-4.2, p= 0.015). Present results showed that the frequency of combined polymorphism GSTT1/M1 null genotypes were not statistically significant. GSTT1 and GSTM1 showed no statistical significance between patients and control group in relation to both clinical and laboratory findings. We have observed that GSTT1 null genotypes were high among Egyptian sickle cell anemia patients and both GSTT1 and GSTM1 null genotypes were not related to both clinical and laboratory findings in SCD patients.

Keywords: SCD, Polymorphism, GSM1, GST1

ÖZET

Mısırlı Orak Hücreli Anemili Olgularda GSTM1 ve GSTT1 Polimorfizmi

Glutathione S-transferaz gen delesyonları detoksifikasyon ajanları olarak bilinir ve oksidatif hasara yol açarlar. Farklı çalışmalararda, null allel frekanslarında varyasyonlar gözlemlemiştir. Bu çalışmada orak hücre anemisi olguları GSTM1 ve GSTT1 null genotip prevalansını araştırdık, 37 orak hücreli anemik ve 40 kontrol oltuda. Glutathione S-transferaz (GSTM) gen delesyonu frekans incelendi. Tam kan sayımı sonuçları otomatik hücre analizörü ile elde edildi. Hemoglobin F, hemoglobin A, hemoglobin A2 ve hemoglobin S seviyeleri ölçülüd. Hastaların tanıları yüksek performanslı likid kromatografı tekniği ile konuldu. GST null genotipi polimeraz zincir reaksiyonu (PCR) method ile saptandı. Orak hücre anemisi oltuları GSTM1-null genotip prevalans %37.8, kontrol grubunda ise %55.0 olarak saptandı (OR= 0.9, 95% CI= 0.3-2.8, p= 0.24). GSTT1 null genotip taşıyan birey frekans orak hücreli anemik olgularında daha yüksekti (%64.9 vs. 42.5%) (Odds Ratio, OR= 2.5, 95% Confidence Interval, CI= 1.8-4.2, p= 0.015). GSTT1/M1 null genotipinin kombinе frekansında anlamlı bir fark bulunmadı. GSTT1 ve GSTM1 klinik ve laboratuvar bulguları açısından her iki gruba benzerdi. Sonuç olarak, GSTT1 null genotipi Mısırlı orak hücre anemik olgularında daha yüksek olarak bulundu, ve gerek GSTT1 gerekse GSTM1 null genotipleri ile klinik ve laboratuvar sonuçların arasında bir ilişki saptayamadık.

Anahtar Kelimeler: Orak hücreli anemi, Polimorfizm, GSTM1, GST1

doi: 10.4999/uhod.13025
INTRODUCTION

According to the World Health Organization, 270 million people possess genes that determine abnormal hemoglobins.\(^1\)\(^2\) Hb S is originated as a point mutation from the GAG (glutamic acid) codon to the GTG (Valine) codon in the sixth position of the β-globin chain. This substitution leads to alterations in the stability and solubility of the molecule and promotes polymerization in conditions with low oxygen tension.\(^7\)

Sickle cell disease (SCD) has become one of the best characterized monogenic human disorders. Many studies have aimed to investigate genetic variations that could explain why only some patients tolerate and respond to this treatment, while the rest still need to be treated with blood transfusion-based strategies.\(^4\) The formation of this new Hb type (HbS) in SCD may alter the delicate balance of free-radical generation and anti-oxidant defense systems in red blood cells, which are a significant source of free radicals in biological systems.\(^6\)

In the deoxygenated state, the HbS tends to aggregate into rod like polymers, resulting in the deformed sickle shape and rigidity of red blood cells (RBCs) characteristic of this condition.\(^5\) Normal RBCs are usually subjected to oxidative stress as a result of continuous reactive oxygen species (ROS) production that accompanies Hb autoxidation. Autoxidation leads to SCD-derived oxidative stress consequences that include an increase in membrane lipid peroxidation levels and alterations in anti-oxidant defense system.\(^7\,\(^8\)

An altered glutathione (GSH) metabolism in association with increased oxidative stress has been implicated in the pathogenesis of many diseases.\(^9\) Alterations in GSH concentration have been demonstrated in many pathological conditions including SCD.\(^10\) Glutathione S-transferases (GST) are a family of enzymes involved in phase-II detoxification of endogenous and xenobiotic compounds. Polymorphisms in GST genes have been associated with susceptibility to different diseases.\(^11\) The clinical severity and hematological manifestations of sickle cell anemia are varied and are influenced by the participation of several genes in modulating the phenotype of sickle cell disease; polymorphisms of these genes may be related to the different manifestations between individuals.\(^12\)

Many genetic factors such as α-thalassemia, fetal hemoglobin synthesis, and β-globin haplotype have been identified, but none of these can fully explain the differences in clinical expression observed in SCD patients. Probably, there are other elements that contribute to the many phenotypes of the disease.\(^13\,\(^14\) In SCD, previous reviews have reported that several of these polymorphisms are associated not only with the degree of anemia, but also with pain rate, prevalence of stroke, leg ulcers, pulmonary hypertension, hepato-biliary complications and priapism, among other several clinical aspects.\(^15\) Glutathione S-transferases (GSTs) constitute multi-functional enzymes that are coded by at least eight distinct loci: α (GSTA); µ (GSTM); θ (GSTT); π (GSTP); σ (GSTS); κ (GSK); Ω (GSTO); and ζ (GSTZ), each one composed of one or more homodimeric or heterodimeric isoforms. These enzymes are involved in the conjugation reactions between glutathione (GSH) and a variety of potentially toxic and carcinogenic compounds. Additionally, GSTs display peroxidase activity and this can protect against oxidative damage.\(^16\,\(^17\) The deficiency in the activity of this enzyme can be derived from the inherited GSTs polymorphisms; GSTT1 (22q11.23), GSTM1 (1q13.3) and GSTP1 (11q13).\(^18\) Associations of GSTM1 and/or GSTT1 null genotypes with aplastic anemia and Fanconi anemia have been reported.\(^19\,\(^20\) In Egypt, there is no literature published on GST deletions in SCD. Thus the aim of this study was to estimate the prevalence of the GSTM1 and GSTT1 null genotypes and to analyze their effect on clinical severity of SCD patients.

MATERIALS AND METHODS

Participants were SCD patients attending the outpatient clinic of hematology units of Mansoura University Children Hospital. Clinical as well as demographic data were obtained from medical records and interviews with the patients or their parents. Informed consent was obtained from all patients and/or their parents. Thirty seven Egyptian subjects were included in the study (15 males and 22 females; mean age: 9.6 years old; range: 4-17 years old). Forty healthy subjects were included in the study as control group who were healthy and without medical history (15 males and 25 females;
mean age: 8.2 years old; range: 5-16 years old).

About 5 ml blood samples were collected from patients and controls after informed consent was received from their parents. Hemoglobin (Hb F, Hb A1, Hb A2 and Hb S) was measured and the diagnosis of patients was performed by high performance liquid chromatography (HPLC, Bio Rad, USA).

**Blood Samples and DNA Extraction**

Blood samples of 5 ml were obtained from all cases and collected in sterile EDTA tubes. Then, whole blood was stored at –20°C until use. Genomic DNA was extracted from whole blood using the established protocol for DNA extraction from blood samples using DNA extraction minikit (QIAGEN, Inc Chasworthy, CA).

**Analysis of GSTM1 and GSTT1 Polymorphism**

The genetic polymorphism analyses for the GSTM1 and GSTT1 genes was determined by the PCR with using a housekeeping β-globin gene an internal control (Figure 1 and 2).

PCR amplifications were performed in a total volume of 25 µL containing 50 ng genomic DNA, 1X PCR buffer, 3 mM MgCl₂, 400 µM dNTPs, 1.5 U Taq polymerase (Hoffman-LaRoche) and 4 µM of each primer as follows: GSTM1 forward primer 5’-GAACTCCCTGAAAAGCTAAAGC-3’, reverse primer 5’-GTTGGGCTCAAATATACGGTGG-3’, GSTT1 forward primer 5’-TTCTTACTGGTCTTCATCTC-3’, reverse primer 5’-TCACCGGATCATGGCCAGCA-3’ and β-globin forward primer 5’-CAACTTCATCCACGTCTTACC-3’, reverse primer 5’-GAAGAGCCAAGGACAGGTAC-3’. Thermal cycling conditions were as follows: an initial denaturation step at 95°C for 5 min, 35 cycles at 94°C for 1 min, 60°C for 1 min and 72°C for 1 min, and a final extension step at 72°C for 5 min. The amplification products were size separated on 2% agarose gels and visualized by ethidium bromide staining. GSTM1 & GSTT1 genotypes were determined by the presence and absence (null) of bands of 230 bp and 112 bp, respectively, with an internal control of 500 bp.

**Statistical Analysis**

The Statistical Program SPSS for windows version 15.0 had been used in data entry and analysis. Descriptive and analytic statistics were performed. Statistical significance was determined at the 95 percent confidence interval level. The lowest accepted level of significance was 0.05 or less. Associations between the GSTM1, GSTT1 polymorphisms and SCD patients were estimated using odds ratios (ORs) and 95% confidence intervals (95% CIs).
RESULTS
The rate of GSTM1 null mutation was 37.8% in children with SCD, while it was 55.0% in the control group. But the difference was not statistically significant (OR= 0.9, 95% CI= 0.3-2.8, p= 0.24) (Table 1). The frequency of individuals carrying the GSTT1 null mutation was higher in SCD patients (64.9%) compared to controls (42.5%) (OR= 2.5, 95% CI= 1.8-4.2, p= 0.015). Therefore GSTT1 null genotype may be a risk factor for SCD (Table 1). Whereas no significant differences between cases and control were found in the genotype prevalence of the combined GSTM1 and GSTT1 null genotypes (p= 0.19). Details of the frequencies of GST deletions are given in Table 1. We didn’t find any significant association between both GSTT1 and GSTM1 null genotypes and clinical severity of the disease in SCD patients (Table 2). In addition, both GSTT1 and GSTM1 null genotypes were not related to the laboratory findings in SCD patients (Table 3).

DISCUSSION
Sickle cell disease shows a pathophysiology that involves multiple changes in sickle cell erythrocytes, vaso-occlusive episodes, hemolysis, and activation of inflammatory mediators, endothelial cell dysfunction, and oxidative stress. These events complicate treatment and culminate in the development of manifestations such as anemia, pain crises and multi-organ dysfunction.

The unexpected clinical diversity in a monogenic disease such as SCD has led to countless genetic studies and current knowledge has evolved, together with technological development in molecular

<p>| Table 1. Frequency of GSTM1 and GSTT1 genotypes in sickle cell anemia patients and controls |
|---------------------------------|------------------|---------|---------|---------|---------|</p>
<table>
<thead>
<tr>
<th>Genotype</th>
<th>Sickle cell anemia</th>
<th>Control</th>
<th>p</th>
<th>OR</th>
<th>95%</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSTM1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>23 (62.1%)</td>
<td>18 (45.0%)</td>
<td>0.24</td>
<td>0.9</td>
<td>0.3-2.8</td>
</tr>
<tr>
<td>Absent</td>
<td>14 (37.8%)</td>
<td>22 (55.0%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSTT1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>13 (35.1%)</td>
<td>23 (57.5%)</td>
<td>0.015</td>
<td>2.5</td>
<td>1.8-4.2</td>
</tr>
<tr>
<td>Absent</td>
<td>24 (64.9%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSTM1/GSTT1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>10 (27.0%)</td>
<td>14 (30.0%)</td>
<td>0.19</td>
<td>1.2</td>
<td>0.9-2.7</td>
</tr>
<tr>
<td>Absent</td>
<td>8 (21.6%)</td>
<td>11 (27.5%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| Table 2. GSTM1 Polymorphism and clinical presentation correlation |
|---------------------------------|-----------------|---------|---------|---------|---------|</p>
<table>
<thead>
<tr>
<th>P</th>
<th>SCA without GSTT1</th>
<th>SCA with GSTT1</th>
<th>P</th>
<th>SCA without GSTT1</th>
<th>SCA with GSTT1</th>
</tr>
</thead>
<tbody>
<tr>
<td>G</td>
<td>SC with GSTT1</td>
<td>SC with GSTT1</td>
<td>SC with GSTT1</td>
<td>SC with GSTT1</td>
<td>SC with GSTT1</td>
</tr>
<tr>
<td>0.3</td>
<td>6 (46.1%)</td>
<td>11 (45.8%)</td>
<td>0.08</td>
<td>9 (39.1%)</td>
<td>5 (35.7%)</td>
</tr>
<tr>
<td>0.1</td>
<td>4 (30.7%)</td>
<td>7 (29.1%)</td>
<td>0.6</td>
<td>7 (30.4%)</td>
<td>4 (28.5%)</td>
</tr>
<tr>
<td>0.4</td>
<td>2 (15.3%)</td>
<td>4 (16.6%)</td>
<td>0.4</td>
<td>2 (8.6%)</td>
<td>1 (7.1%)</td>
</tr>
<tr>
<td>0.5</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0.9</td>
<td>1 (4.3%)</td>
<td>1 (7.1%)</td>
</tr>
<tr>
<td>0.5</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0.5</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
</tr>
</tbody>
</table>
biology. Evolution from the basic identification of polymorphic sites has provided the tools to discover the genetic complexity that affects genotype–phenotype correlation.12 Some studies involving different polymorphisms of GST have been performed in patients with SCD.22 Our study showed that GSTT1 null genotype was significantly higher amongst the SCD patients than the healthy control group. This was in agreement with previous study that was performed in India which reported a higher mean frequency of GSTT1 deletions in SCD patients.23

In our study, the prevalence of GSTM1 and GSTT1 null genotypes in the control group were 55% and 42.5% respectively. However, some studies found lower frequency rates. They reported that GSTM1 null genotype was 44% and the GSTT1 null genotype was 14.7% in Egyptian population.24 Combined polymorphism analysis of both genes in our study revealed that 27.5% of the control group had deleted genotype of both genes. This was higher than previous study in Egyptian population. The reason for this difference between both studies was attributed to regional variation of the controls included in these studies.

Human GSTs have been well characterized as ethnic-dependent polymorphism frequencies and largely divergent among populations around the world.16,25 The frequency data obtained for the SCD patients group presented higher frequencies for the null GSTM1 (21.6%) genotype when compared with the frequencies obtained for Brazilian population.20,26 The association of GSTM1, GSTT1 and GSTP1 polymorphisms with various diseases such as inflammatory diseases and responses in the metabolism, efficacy and toxicity of certain drugs have been widely investigated.28,29 Knowledge of the variations in frequency of GSTM1 and GSTT1 null genotype in different population may help to explain differential responses to toxic chemicals.30 Homozygous deletion of the genes at the corresponding gene loci causes the absence of the specific enzymatic activity.31 GSTM1 null genotype has been shown to be 31 to 66% in Asians and Indians.32 On the other hand, GSTM1 deletion polymorphism for African-Americans was found to be 23-35% and for Chileans was 21%.33,35

Despite the small sample size, the study demonstrated that Egyptian SCD patients have high frequency of GSTT1 gene polymorphism but their effects on clinical presentation is not obvious; however, further detailed studies at the molecular level, with a larger sample size are required to show the mechanisms that influence the clinical presentation of SCD in Egyptian population.

**REFERENCES**


---

**Table 3. GSTT1 Polymorphism and Laboratory findings correlation**

<table>
<thead>
<tr>
<th>P</th>
<th>SCA with no GSTT1 null genotype</th>
<th>SCA with GSTT1 null genotype</th>
<th>P</th>
<th>SCA with no GSTT1 null genotype</th>
<th>SCA with GSTT1 null genotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.32</td>
<td>13.4 ± 1.8</td>
<td>14.1 ± 2.9</td>
<td>0.07</td>
<td>11.2 ± 3.3</td>
<td>13.5 ± 3.5</td>
</tr>
<tr>
<td>0.07</td>
<td>8.7 ± 2.5</td>
<td>8.6 ± 1.6</td>
<td>0.09</td>
<td>7.5 ± 2</td>
<td>9.4 ± 3</td>
</tr>
<tr>
<td>0.10</td>
<td>3.2 ± 0.68</td>
<td>2.9 ± 0.73</td>
<td>0.14</td>
<td>3 ± 0.3</td>
<td>3.2 ± 0.25</td>
</tr>
<tr>
<td>0.07</td>
<td>396 ± 29</td>
<td>412 ± 27</td>
<td>0.09</td>
<td>463 ± 45</td>
<td>479 ± 25</td>
</tr>
<tr>
<td>0.09</td>
<td>7.95 ± 1.35</td>
<td>6.26 ± 1.43</td>
<td>0.10</td>
<td>7.77 ± 2.25</td>
<td>7.54 ± 2.26</td>
</tr>
</tbody>
</table>

WBC Count (x10^9/L) Mean ± SD

Neutrophil Count (x10^9/L) Mean ± SD

Lymphocyte Count (x10^9/L) Mean ± SD

Mean Platelet Count (x10^9/L) Mean ± SD

Haemoglobin (g/dl) Mean ± SD


Correspondence
Rabab ALY, MD.
Mansoura University Faculty of Medicine,
Department of Clinical Pathology
MANSOURA / EGYPT

e-mail: rababzeadah@yahoo.com